Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrice Barlesi

Showing results (1-10 of 343) with videos related to

Pageof 35
Sort By:
The Lancet. Oncology|November 29, 2008
Lung cancer: moving forward with tailored strategiesFabrice Barlesi
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|April 6, 2010
Targeted therapies in non-small-cell lung cancer (NSCLC): how to proceed to aim at the good target?Fabrice Barlesi
La Revue Du Praticien|October 21, 2009
[Small-cell lung cancer]Fabrice Barlesi
Expert Review of Molecular Diagnostics|April 25, 2019
Companion diagnostic tests for treatment of lung cancer patients: what are the current and future challenges?Paul Hofman, Fabrice Barlesi
Annales De Pathologie|November 9, 2010
[Which type of diagnostic and pretreatment sampling should be chosen and for which patient?]Sabine Marco, Fabrice Barlesi
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|August 4, 2021
Precision follow-up for resected non-small-cell lung cancer: is it ready for prime time?Olaf Mercier, Fabrice Barlesi
Expert Opinion on Biological Therapy|July 15, 2017
MEDI 4736 (durvalumab) in non-small cell lung cancerArnaud Jeanson, Fabrice Barlesi
The Lancet. Oncology|April 7, 2020
Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitorsFabrice Barlesi, Pascale Tomasini
Anti-Cancer Drugs|January 26, 2011
Targeted therapies in malignant pleural mesothelioma: a review of clinical studiesLaurent Greillier, Sabine Marco, Fabrice Barlesi
Therapeutic Advances in Medical Oncology|February 17, 2018
Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapyFanny Jean, Pascale Tomasini, Fabrice Barlesi
Pageof 35

Showing results (1-10 of 343) with videos related to

Sort By:
Pageof 35
The Lancet. Oncology|November 29, 2008
Lung cancer: moving forward with tailored strategiesFabrice Barlesi
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|April 6, 2010
Targeted therapies in non-small-cell lung cancer (NSCLC): how to proceed to aim at the good target?Fabrice Barlesi
La Revue Du Praticien|October 21, 2009
[Small-cell lung cancer]Fabrice Barlesi
Expert Review of Molecular Diagnostics|April 25, 2019
Companion diagnostic tests for treatment of lung cancer patients: what are the current and future challenges?Paul Hofman, Fabrice Barlesi
Annales De Pathologie|November 9, 2010
[Which type of diagnostic and pretreatment sampling should be chosen and for which patient?]Sabine Marco, Fabrice Barlesi
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|August 4, 2021
Precision follow-up for resected non-small-cell lung cancer: is it ready for prime time?Olaf Mercier, Fabrice Barlesi
Expert Opinion on Biological Therapy|July 15, 2017
MEDI 4736 (durvalumab) in non-small cell lung cancerArnaud Jeanson, Fabrice Barlesi
The Lancet. Oncology|April 7, 2020
Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitorsFabrice Barlesi, Pascale Tomasini
Anti-Cancer Drugs|January 26, 2011
Targeted therapies in malignant pleural mesothelioma: a review of clinical studiesLaurent Greillier, Sabine Marco, Fabrice Barlesi
Therapeutic Advances in Medical Oncology|February 17, 2018
Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapyFanny Jean, Pascale Tomasini, Fabrice Barlesi
Pageof 35